Pena, L., Barohn, R. J., Dimachkie, M. M., Kishnani, P. S., Ladha, S., Mengel, K.-E., … Schoser, B. (2019). NEO1 and NEO-EXT studies: Long-term safety of repeat avalglucosidase alfa dosing for 4.5 years in late-onset Pompe disease patients. In Molecular Genetics and Metabolism (Vol. 126, pp. S115–S116). Elsevier BV. https://doi.org/10.1016/j.ymgme.2018.12.294

Pena, Loren, Richard J. Barohn, Mazen M. Dimachkie, Priya S. Kishnani, Shafeeq Ladha, Karl-Eugen Mengel, Sabrina Sacconi, et al. “NEO1 and NEO-EXT studies: Long-term safety of repeat avalglucosidase alfa dosing for 4.5 years in late-onset Pompe disease patients.” In Molecular Genetics and Metabolism, 126:S115–16. Elsevier BV, 2019. https://doi.org/10.1016/j.ymgme.2018.12.294.

Pena L, Barohn RJ, Dimachkie MM, Kishnani PS, Ladha S, Mengel K-E, et al. NEO1 and NEO-EXT studies: Long-term safety of repeat avalglucosidase alfa dosing for 4.5 years in late-onset Pompe disease patients. In: Molecular Genetics and Metabolism. Elsevier BV; 2019. p. S115–6.

Pena, Loren, et al. “NEO1 and NEO-EXT studies: Long-term safety of repeat avalglucosidase alfa dosing for 4.5 years in late-onset Pompe disease patients.” Molecular Genetics and Metabolism, vol. 126, no. 2, Elsevier BV, 2019, pp. S115–16. Crossref, doi:10.1016/j.ymgme.2018.12.294.

Pena L, Barohn RJ, Dimachkie MM, Kishnani PS, Ladha S, Mengel K-E, Sacconi S, Van Damme P, Vissing J, Haack KA, Hug C, Johnson J, Sensinger C, Schoser B. NEO1 and NEO-EXT studies: Long-term safety of repeat avalglucosidase alfa dosing for 4.5 years in late-onset Pompe disease patients. Molecular Genetics and Metabolism. Elsevier BV; 2019. p. S115–S116.